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Abstract
Background: Bone mass is maintained by continuous remodeling through repeated cycles of bone resorption by
osteoclasts and bone formation by osteoblasts. This remodeling process is regulated by many systemic and local factors.
Methodology/Principal Findings: We identified collagen triple helix repeat containing-1 (Cthrc1) as a downstream target of
bone morphogenetic protein-2 (BMP2) in osteochondroprogenitor-like cells by PCR-based suppression subtractive
hybridization followed by differential hybridization, and found that Cthrc1 was expressed in bone tissues in vivo.T o
investigate the role of Cthrc1 in bone, we generated Cthrc1-null mice and transgenic mice which overexpress Cthrc1 in
osteoblasts (Cthrc1 transgenic mice). Microcomputed tomography (micro-CT) and bone histomorphometry analyses
showed that Cthrc1-null mice displayed low bone mass as a result of decreased osteoblastic bone formation, whereas Cthrc1
transgenic mice displayed high bone mass by increase in osteoblastic bone formation. Osteoblast number was decreased in
Cthrc1-null mice, and increased in Cthrc1 transgenic mice, respectively, while osteoclast number had no change in both
mutant mice. In vitro, colony-forming unit (CFU) assays in bone marrow cells harvested from Cthrc1-null mice or Cthrc1
transgenic mice revealed that Cthrc1 stimulated differentiation and mineralization of osteoprogenitor cells. Expression
levels of osteoblast specific genes, ALP, Col1a1, and Osteocalcin, in primary osteoblasts were decreased in Cthrc1-null mice
and increased in Cthrc1 transgenic mice, respectively. Furthermore, BrdU incorporation assays showed that Cthrc1
accelerated osteoblast proliferation in vitro and in vivo. In addition, overexpression of Cthrc1 in the transgenic mice
attenuated ovariectomy-induced bone loss.
Conclusions/Significance: Our results indicate that Cthrc1 increases bone mass as a positive regulator of osteoblastic bone
formation and offers an anabolic approach for the treatment of osteoporosis.
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Introduction
Bone modeling is initiated by osteoblastic differentiation of
mesenchymal cells into preosteoblasts. Preosteoblasts then differen-
tiate into functional osteoblasts producing bone matrix proteins,
including type I collagen, osteopontin, and osteocalcin to form bone
tissues. Bone is constantly remodeled through bone formation by
functional osteoblasts and bone resorption by osteoclasts which arise
from monocytic cells, and bone mass is maintained by their precise
balance [1–3]. Recently,significant advances have been made inour
understandings of the factors that regulate the balance between
osteoblastic bone formation and osteoclasticbone resorption, but the
mechanisms have not been fully elucidated.
Bone morphogenetic proteins (BMPs) are potent osteogenic
agents that induce differentiation of mesenchymal cells toward an
osteoblastic lineage and stimulate the differentiation and functions
of osteoblasts during a process of bone modeling [4–6].
Postnatally, BMP signaling regulates osteoblastic bone formation
and osteoclastic bone resorption in bone remodeling [7]. Recent
studies show that osteoblast-specific inhibition of BMP signals in
mice affects postnatal bone mass [8–12]. Osteoblast-specific
Bmpr1a deficient mice show reduced bone volume and bone
formation rates with normal osteoblast number due to impaired
osteoblast function at 3 months old and increased bone volume
probably due to reduced osteoclastic bone resorption at 10 months
old [11]. Transgenic mice that osteoblast-specifically overexpress
noggin, the BMP inhibitor, display reduced bone mineral densities
and bone formation rates due to impaired osteoblast function
[8,9]. Mice carrying a targeted deletion of Tob, which is a member
of a new antiproliferative protein family and represses BMP-
induced Smad-dependent transcription in osteoblasts, have
increased bone mass due to increased osteoblast numbers and
acceleration of the bone formation rates [12]. Thus, BMPs are key
molecules that control bone modeling and bone remodeling.
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3174To identify the molecules that regulate bone modeling and/or
bone remodeling as a downstream target of BMP signaling, we
compared the mRNAs expressed in BMP2-untreated and BMP2-
treated ATDC5 osteochondroprogenitor-like cells by PCR-based
suppression subtractive hybridization followed by differential
hybridization, and identified a cDNA upregulated by BMP2, that
encoded Collagen triple helix repeat containing protein 1 (Cthrc1).
Cthrc1 is a 30-kD glycosylated secreted protein containing a short
collagen-like motif with 12 Gly-X-Y repeats similar to the collagen
domains present in the C1q/tumor necrosis factor a related
proteins [13]. Cthrc1 is transiently expressed in the arterial wall in
response to injury, suggesting that Cthrc1 is involved in vascular
remodeling by limiting collagen matrix deposition and promoting
cell migration [13]. A recent study shows that neointimal lesion
formation and adventitial collagen deposition in response to
carotid artery ligation are reduced in transgenic mice overex-
pressing Cthrc1 under the control of cytomegalovirus promoter
[14]. According to expression analysis of Cthrc1, abundant
expression of Cthrc1 is observed in developing skeleton during
embryogenesis and in the bone matrix and periosteum in adult
mice [15].
In this study, we generated Cthrc1-null mice and transgenic mice
that overexpress Cthrc1 under the control of Col1a1 osteoblast-
specific promoter. Cthrc1-null mice developed a low-bone-mass-
phenotype as a result of reduced bone formation, while the
transgenic mice exhibited a high-bone-mass-phenotype caused by
enhanced bone formation. In vitro analyses showed that Cthrc1
stimulated osteoblast proliferation and differentiation. Thus, our
results indicate that Cthrc1 is a positive regulator of osteoblastic
bone formation.
Results
Cthrc1 is expressed in bone
To identify potential osteoblast-specific proteins as downstreams
of BMPs, we performed two-step screening consisting of PCR-
based suppression subtractive hybridization followed by differen-
tial hybridization using the poly(A)
+ RNA extracted from BMP2-
untreated and BMP2-treated ATDC5 cells, and identified a cDNA
encoding Cthrc1(Figure S1A). In vitro, Cthrc1 was expressed in
MC3T3-E1 osteoblastic cells and differentiated ATDC5 cells, but
not in C3H10T1/2 fibroblastic cells and C2C12 myoblastic cells
(Figure S1B). We next assessed the expression of Cthrc1 in various
adult mouse tissues by northern blot analysis, and Cthrc1 was
expressed in bone but not in the other adult mouse tissues
examined (Figure S1C). During the skeletogenesis in the limb buds
of mouse embryos, Cthrc1 was expressed in the mesenchymal
condensation in E13.5 and in the bone tissues in E16.5 (Figure
S1D). In addition, the expression levels of Cthrc1 increased during
mouse embryogenesis (Figure S1E). These results suggest that
Cthrc1 plays an important role in bone modeling or remodeling.
Low bone mass and decreased bone formation in Cthrc1-
null mice
To investigate the physiological role of Cthrc1 in bone, we
inactivated the Cthrc1 gene in mouse embryonic stem cells by
homologous recombination. In the target strategy, an IRES-lacZ-
pA-loxP-flanked neomycin resistance expression cassette was
introduced into exon 2 which codes a short Gly-X-Y collagen
triple helix repeat domain (Figure 1 A and B). As shown in
Figure 1C, Cthrc1 RNA was absent in E16.5 Cthrc1-null embryo,
indicating that the mutation was a null mutation. Homozygous
Cthrc1 mutant mice were born at the expected Mendelian ratio
and grew normally in comparison with their wild-type littermates
(data not shown). X-gal staining of heterozygous Cthrc1 mutant
embryos revealed the expression of Cthrc1 in bone-forming tissues
in E12.5 embryos and in bones and periarticular cartilages in
E16.5 embryos, which corresponded to the results of in situ
hybridization (Figure 1D and Figure S2A). Skeletal preparations
showed no obvious skeletal phenotypes in Cthrc1-null newborn
mice (Figure S2B). In situ hybridization analyses showed
comparable expression of osteoblast marker genes, Runx2 and
Col1a1, and chondrocyte marker genes, Col2a1 and Col10a1
between E16.5 Cthrc1-null embryos and their wild-type littermates
(Figure S3A), suggesting that Cthrc1 has no apparent effect on
skeletal development. However, histological analyses of decalcified
adult bone tissues revealed that the number and thickness of
trabecular bones were reduced in Cthrc1-null mice, compared with
their wild-type littermates (data not shown). This result suggested
that Cthrc1 may regulate bone remodeling postnatally. To test this
hypothesis, we performed bone histomorphometric analyses and
microcomputed tomography (micro-CT) analyses of 2-month-old
Cthrc1-null and wild-type mice. Micro-CT analyses of tibiae
showed that the trabecular bone mass in Cthrc1-null mice was
approximately 70% of that in wild-type mice (Figure 2 A and B).
Bone histomorphometric and micro-CT analyses showed a
significant decrease in trabecular number (Tb.N) and osteoblast
number (Ob.N/BS) in Cthrc1-null mice, while trabecular thickness
(Tb.Th) and tartrate-resistant acid phosphatase (TRAP)-positive
osteoclast number (Oc.N/BS) had no change in Cthrc1-null mice
(Figure 2C–E and Figure S4A). In addition, the osteoblast surface
(Ob.S/BS) in Cthrc1-null mice, which represents the proportion of
the bone surface covered with osteoblasts, was approximately 40%
less than that in wild-type mice, and the osteoclast surface (Oc.S/
BS), which represents the proportion of the bone surface covered
with osteoclasts, showed no significant difference between Cthrc1-
null and wild-type mice (Figure 2F and Figure S4A). To analyze
osteoblast proliferation in vivo, we performed BrdU incorporation
assays in the calvaria of Cthrc1-null and wild-type littermates, and
found that the percentage of proliferating cells was decreased by
approximately 30% in Cthrc1-null mice (Figure 2G). Moreover,
double-labeling analyses with calcein, a marker of newly formed
bone, showed that the bone formation rate was significantly
decreased in Cthrc1-null mice (Figure 2H). Thus, these results
indicate that the decreased bone mass in Cthrc1-null mice is due to
the suppression of osteoblastic bone formation, not due to an
acceleration of osteoclastic bone resorption.
High bone mass and increased bone formation in
transgenic mice overexpressing Cthrc1 in osteoblasts
To determine if Cthrc1 is sufficient to increase bone mass, we
next generated transgenic mice that specifically overexpressed
36HA tagged Cthrc1 in osteoblasts under the control of the Col1a1
2.3 kb osteoblast-specific promoter (Figure 3A). Immunohisto-
chemistry with antibody against the HA-epitope tag showed
specific expression of 36HA tagged protein in bone collars,
periosteum, and trabecular bones (Figure 3B). Hemizygous Cthrc1
transgenic mice were born at the expected Mendelian ratio and
grew normally in comparison with their wild-type littermates (data
not shown). Skeletal preparations showed no apparent skeletal
phenotypes in newborn hemizygous transgenic mice (Figure S2C).
In addition, in situ hybridization analyses revealed that overex-
pression of Cthrc1 in osteoblasts did not affect the expression of
the osteoblast markers, Runx2 and Col1a1, and chondrocyte
markers, Col2a1 and Col10a1, in E16.5 mouse embryos (Figure
S3B). As we found an osteopenic phenotype in adult Cthrc1-null
mice, we analyzed bone in adult Cthrc1 transgenic mice. Micro-CT
analyses of tibiae showed that the trabecular bone mass in
Cthrc1 in Bone Formation
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greater than that in wild-type mice (Figure 3C and D). Likewise,
bone histomorphometric and micro-CT analyses showed signifi-
cant increase in trabecular number (Tb.N) and osteoblast number
(Ob.N/BS) in transgenic mice, while trabecular thickness (Tb.Th)
and TRAP-positive osteoclast number (Oc.N/BS) had no change
between transgenic mice and wild-type mice (Figure 3E–G and
Figure S4C). The osteoblast surface (Ob.S/BS) in transgenic mice
was approximately 40% greater than that in wild-type mice, while
there was no difference in the osteoclast surface (Oc.S/BS)
between transgenic mice and wild-type mice (Figure 3H and
Figure S4C). BrdU incorporation assays showed that the
percentage of proliferating osteoblasts was increased by approx-
imately 35% in transgenic mice (Figure 3I). Furthermore, double-
labeling analyses with calcein showed a marked increase in the
bone formation rate in transgenic mice (Figure 3J). Thus, these
data indicate that the increase in bone mass in Cthrc1 transgenic
mice is due to the stimulation of osteoblastic bone formation.
Cthrc1 stimulates osteoblast proliferation and
differentiation
Both the loss-of-function and gain-of-function analyses using
mouse genetics approaches indicate that Cthrc1 positively
regulates osteoblastic bone formation in vivo. To clarify the
functions of Cthrc1 in osteoblasts, we isolated osteoblasts from
the calvaria of wild-type (Cthrc1
+/+ osteoblasts) and Cthrc1-null
(Cthrc1
2/2 osteoblasts) newborn mice and analyzed the effects of
Cthrc1 on osteoblast proliferation and differentiation in vitro. BrdU
incorporation in Cthrc1
2/2 osteoblasts was 40% less than that in
Cthrc1
+/+ osteoblasts (Figure 4A). Real-time PCR analyses
confirmed that the mRNA levels of the osteoblast marker genes,
ALP, Col1a1, and Osteocalcin were all decreased in Cthrc1
2/2
osteoblasts, whereas the expression level of receptor activator of
nuclear factor kB ligand (RANKL), a major determinant of
osteoclastogenesis, did not differ (Figure 4B and Figure S4B).
We further performed in vitro analyses of osteoprogenitor
frequency and differentiation capacity by colony-forming unit
(CFU) assays. CFU-ALP assays demonstrated that Cthrc1
2/2 bone
marrow cells had dramatically reduced osteoprogenitors, and
mineralized area of CFU-osteoblast (CFU-O) was also reduced by
more than half in Cthrc1
2/2 bone marrow cells, consistent with
decreased functional progenitors (Figure 4C and D). Likewise, we
examined osteoblast proliferation and differentiation in osteoblasts
derived from Cthrc1 transgenic mice (Tg-osteoblasts) in vitro.A s
shown in Figure 4A, BrdU incorporation in Tg-osteoblasts was
25% greater than that in wild-type osteoblasts. The mRNA levels
Figure 1. Generation of Cthrc1-null mice. (A) Structure of the genomic Cthrc1 locus, targeting vector, and targeting allele. Exons are depicted as
closed boxes, and intronic sequences are shown as solid lines. IRES-LacZ-pA-loxP-flanked PGK-neo-bpA cassettes are depicted as open boxes. S, SacI;
B, BamHI. (B) Southern blot analysis of fetal genomic DNA. Genomic DNA isolated from the skin was digested with SacI and then hybridized with the
59 or 39 probe. The wild-type and the mutant allele were detected with the 59 probe as 13.1-kb and 6.5-kb fragments and with the 39 probe as 13.1-kb
and 9.1-kb fragments, respectively. (C) RT-PCR analysis of Cthrc1 transcript in E16.5 wild-type and Cthrc1-null littermates. (D) Whole-mount X-gal
staining of E16.5 heterozygous Cthrc1 embryo. WT: wild-type mice; KO: Cthrc1-null mice; +/2: Cthrc1 heterozygous mice.
doi:10.1371/journal.pone.0003174.g001
Cthrc1 in Bone Formation
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whereas the expression level of RANKL did not differ (Figure 4B
and Figure S4D). CFU assays showed that the frequency of
osteoprogenitors and mineralized area of CFU-O were signifi-
cantly increased in Cthrc1 transgenic mice (Figure 4C and D).
Thus, these results indicate that Cthrc1 accelerates bone formation
by stimulating osteoblast proliferation and differentiation, resulting
in increased postnatal bone volume.
Cthrc1 attenuates ovariectomy (OVX)-induced bone loss
In view of an anabolic effect of Cthrc1 on bone formation, we
tested whether Cthrc1 may impact bone mass in the OVX mice,
an established preclinical disease model of postmenopausal
osteoporosis [16]. Eight-week-old Cthrc1 transgenic and wild-type
mice were ovariectomized or sham-operated, and four weeks after
operation, metaphyseal regions of tibiae were analyzed by micro-
CT. OVX induced 47% trabecular bone loss in wild-type mice,
and 38%, in transgenic mice (Figure 5A and B), and trabecular
bone mass in OVX transgenic mice was only 17% less than that in
sham-operated wild-type mice. Trabecular number, which was
reduced by ovariectomy in both wild-type and transgenic mice,
did not significantly differ between sham-operated wild-type mice
and OVX transgenic mice (Figure 5C). Trabecular thickness,
which was reduced in OVX wild-type mice, had no significant
difference between sham-operated and OVX transgenic mice
(Figure 5D). These results indicated that stimulatory effect of
Cthrc1 on bone formation partly prevents reduction in bone
volume by ovariectomy. Indeed, increase in bone formation rates
was maintained after ovariectomy in transgenic mice. (Figure 5E).
Thus, Cthrc1 attenuates estrogen deficiency-induced bone loss by
enhanced osteoclastic bone resorption through stimulating osteo-
blastic bone formation.
Discussion
Bone mass is regulated by continuous remodeling which is
based on the balanced action between osteoblastic bone formation
and osteoclastic bone resorption [2]. This process is precisely
coordinated to maintain the bone mass homeostasis mediated by
multiple signaling pathways such as parathyroid hormone,
transforming growth factor-b (TGF-b) and BMP [3,7]. In this
Figure 2. Bone phenotypes of Cthrc1-null mice. (A–D) Micro-CT analyses of tibiae in 2-month-old Cthrc1-null and wild-type mice (n=6). Bone
volume/total volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th) are shown. (E and F) Bone histomorphometric analyses of
vertebrae in 2-month-old Cthrc1-null and wild-type mice (n=6). Osteoblast number/bone surface (Ob.N/BS) and osteoblast surface/bone surface
(Ob.S/BS) are shown. (G) Analyses of osteoblast proliferation in calvaria of 1-week-old Cthrc1-null and wild-type mice by BrdU incorporation assays.
Arrows indicate BrdU positive osteoblasts. (H) Calcein double-labeling of vertebrae in 2-month-old Cthrc1-null and wild-type mice. BFR : Bone
formation rate. WT: wild-type mice; KO: Cthrc1-null mice. Data are shown as the mean6SEM (
*p,0.05).
doi:10.1371/journal.pone.0003174.g002
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formation. In Cthrc1-null mice, bone volume, trabecular number,
osteoblast number, and bone formation rates were significantly
decreased. In Cthrc1 transgenic mice, bone volume, trabecular
number, osteoblast number and bone formation rates were
increased. In vitro, CFU assays in bone marrow cells and analyses
of expression of osteoblast specific genes, ALP, Col1a1, and
Osteocalcin, in osteoblasts revealed that Cthrc1 stimulates differen-
tiation of osteoprogenitor cells and osteoblasts. Furthermore, BrdU
incorporation assays showed that Cthrc1 stimulates osteoblast
proliferation in vitro and in vivo. In contrast, Cthrc1 did not affect
either TRAP-positive osteoclast number and osteoclast surface
in vivo,o rRANKL expression levels in primary osteoblasts.
These findings indicate that Cthrc1 acts as a stimulator of
osteoblastic bone formation, but has no effect on osteoclastic bone
resorption.
BMPs have potent osteogenic effects and control osteoblast
proliferation and differentiation during osteogenesis [6,12,17].
Several studies of cell-specific inactivation or activation of BMP
signals in mice have shown that BMPs regulate postnatal bone
remodeling [8–12]. As shown in previous studies, Cthrc1 is
regulated by TGF-b and BMP4, and a putative Smad binding site
is identified in the promoter region of Cthrc1 [13,18]. We show that
Cthrc1, which is induced by BMP2, is not required for skeletal
development, but is for the maintainance of bone homeostasis,
suggesting that Cthrc1 may act as one of the downstream targets of
BMP-Smad signaling, followed by enhanced expression of
osteoblast specific genes including ALP, Col1a1 and Osteocalcin.
The detail mechanism of Cthrc1 during bone formation is
unclear. Cthrc1 inhibited TGF-b signaling in smooth muscle cells
but not in endotherial cells [14]. Contrary to the effect of Cthrc1 on
osteoblasts in Col1a1 expression in our study, overexpression of
Figure 3. Generation of Cthrc1 transgenic mice and analyses of bone phenotypes. (A) Schematic representation of the Col1a1-Cthrc1
transgene. Poly A: SV40 polyadenylation signal. Arrows indicate the primers for genotyping. (B) Expression of 36HA-tagged Cthrc1 protein in humeri
of E16.5 Cthrc1 transgenic mice. (C–F) Micro-CT analyses of tibiae in 2-month-old Cthrc1 transgenic and wild-type mice (n=6). Bone volume/total
volume (BV/TV), trabecular number (Tb.N) and trabecular thickness (Tb.Th) are shown. (G and H) Bone histomorphometric analyses of vertebrae in 2-
month-old Cthrc1 transgenic and wild-type mice (n=6). Osteoblast number/bone surface (Ob.N/BS) and osteoblast surface/bone surface (Ob.S/BS)
are shown. (I) Analyses of osteoblast proliferation in calvaria of 1-week-old Cthrc1 transgenic and wild-type mice by BrdU incorporation assays. Arrows
indicate BrdU positive osteoblasts. (J) Calcein double-labeling of vertebrae in 2-month-old Cthrc1 transgenic and wild-type mice. BFR: Bone formation
rate. WT: wild-type mice; Tg: Cthrc1 transgenic mice. Data are shown as the mean6SEM (
*p,0.05).
doi:10.1371/journal.pone.0003174.g003
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of Col1a1, and collagen deposition [13,14]. These results suggest that
the functionofCthrc1 differsamong celltypes,orthatCthrc1signals
through its own signaling pathway which is functional in a cell-type
specific manner. In addition, there are discrepancies of phenotypes
between Cthrc1 transgenic micewhich we generated inthis study and
the transgenic mice overexpressing Cthrc1 previously reported [14].
First, transgenic mice we generated display a high-bone-mass
phenotype, whereas transgenic mice previously reported show an
osteopenic phenotype. Second, transgenic mice previously reported
are smaller in size and have a higher rate of postnatal mortality,
whereas transgenic mice we generated are fertile and normal in
appearance and body weight. A possible explanation for these
discrepanciesisthattransgenicmice we generatedoverexpressCthrc1
specifically in osteoblasts under the control of the Col1a1 2.3kb
osteoblast-specific promoter to focus on the function of Cthrc1 in
bones, while transgenic mice previously reported ubiquitously
overexpress Cthrc1 under the control of cytomegalovirus promoter.
Ovariectomy leads to a deficit in bone mineral densities due to
cortical bone modeling and resorption of cancellous bone [19,20].
This change largely results in severe cancellous osteopenia.
Dempster et al. demonstrated that the primary mechanism of
ovariectomy-induced bone loss is osteoclast perforation and
removal of the trabecular plates [21]. Furthermore, a recent study
showed that selective ablation of estrogen receptor a in
differentiated osteoclasts induced trabecular bone loss, similar to
the osteoporotic bone phenotype, caused by inhibition of
osteoclast apoptosis [22]. Thus, ovariectomy-induced bone loss,
a model of postmenopausal osteoporosis, results from an
acceleration of osteoclastic bone resorption, followed by high
bone turnover in which bone resorption exceeds bone formation.
Cthrc1-null mice exhibit cancellous bone loss, and Cthrc1 transgenic
mice increase cancellous bone with no change in osteoclastic bone
resorption. In addition, Cthrc1 stimulates osteoblast proliferation
and differentiation and increases bone formation rates, suggesting
that Cthrc1 prevents cancellous bone loss in ovariectomized mice
by stimulating osteoblastic bone formation. Indeed, bone volume
and trabecular number in OVX transgenic mice were higher than
those in OVX wild-type mice, and the loss of trabecular thickness
by ovariectomy was protected in transgenic mice. Moreover,
increased bone formation rates in transgenic mice were main-
tained after OVX. Considering that Cthrc1 does not affect
Figure 4. Effects of Cthrc1 on osteogenesis. (A) Cell proliferation in primary osteoblasts harvested from Cthrc1-null mice (upper panel) and from
Cthrc1 transgenic mice (lower panel) as shown by BrdU incorporation assays. (B) Expression of early and late osteoblast marker genes in primary
osteoblasts harvested from Cthrc1-null mice (upper panel) and Cthrc1 transgenic mice (lower panel). (C) The total numbers of CFU-ALP in bone
marrow cell cultures derived from Cthrc1-null mice (left) and Cthrc1 transgenic mice (right). (D) The mineralized area of CFU-O in bone marrow cell
cultures derived from Cthrc1-null mice (left) and Cthrc1 transgenic mice (right). WT: wild-type mice; KO: Cthrc1-null mice; Tg: Cthrc1 transgenic mice.
Data are shown as the mean6SEM (
*p,0.05).
doi:10.1371/journal.pone.0003174.g004
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Cthrc1 may attenuate bone loss caused by enhanced osteoclastic
bone resorption induced by OVX.
It is noteworthy in this article that Cthrc1 may have a potential
role in treating osteoporosis, because we observed that osteoblast-
specific overexpression of Cthrc1 in mice attenuates bone loss
which is induced by OVX, an accepted preclinical disease model
of postmenopausal osteoporosis. The function of Cthrc1 as a
stimulator of bone formation without affecting bone resorption is
very promising, because most types of drugs which are currently
used for the treatment of osteoporosis are antiresorptive in nature
and insufficient for restoring bone volume in osteoporotic patients
[23]. Although anabolic agents improve bone mass by stimulating
osteoblast-mediated bone formation, only a single anabolic agent,
parathyroid hormone 1–34 is available to treat osteoporosis at
present [24,25]. Herein, we indicate that Cthrc1 attenuates
estrogen deficiency-induced bone loss by stimulating osteoblastic
bone formation. Hence, Cthrc1 constitutes a potential target of an
anabolic therapy for osteoporosis and the therapeutic effects are
expected to be enhanced with antiresorptive drugs.
Materials and Methods
Suppression subtractive hybridization
ATDC5 cells were cultured for a total of 5 days in DMEM/
Ham’s F12 medium supplemented with 5% FBS and 10 mg/ml
insulin with medium change every other day. Cells were exposed
to 1 mg/ml BMP2 or vehicle for 10 hr. Poly (A)
+ RNA was isolated
from BMP2 -untreated and BMP2 -treated ATDC5 cells by a
single-step method as previously described [26] and analyzed by
suppression subtractive hybridization according to the manufac-
turer’s instruction (PCR-Select cDNA Subtractions Kit, Clontech).
After subtraction, the cDNAs were ligated into pCR2.1 (Invitro-
gen), and these subtracted cDNA libraries were further screened
by differential hybridization (differential screening kit, Clontech).
The cDNA fragment of approximately 500-bp expressed at a high
level in BMP2 -treated ATDC5 cells was identified. Oligo (dT)
primed cDNA library from poly(A)
+ RNA of BMP2 -treated
ATDC5 cells was constructed in lZAP Express vector (Strata-
gene), and 1610
6 plaques were screened with the 500-bp fragment
as a probe as previously described [26].
Figure 5. OVX-induced bone loss is attenuated in Cthrc1 transgenic mice. (A) micro-CT of tibiae from 3-month-old Cthrc1 transgenic and
wild-type mice which were sham-operated or ovariectomized at 2 months of age (n=5). (B–E) Bone volume/total volume (BV/TV) (B), trabecular
number (Tb.N) (C), trabecular thickness (Tb.Th) (D) and bone formation rate (BFR) (E) were assessed by micro-CT or bone histomorphometry. WT: wild-
type mice; Tg: Cthrc1 transgenic mice. Data are shown as the mean6SEM (
*p,0.05).
doi:10.1371/journal.pone.0003174.g005
Cthrc1 in Bone Formation
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A Cthrc1 genomic clone was isolated from a mouse 129SvEv
genomic DNA library. The targeting vector was constructed by
inserting an IRES-LacZ-pA-loxP-flanked neomycin resistance
expression cassette into exon 2 of the Cthrc1 gene. Homologous
recombination in 129SvEv ES clones harboring Protamine 1-Cre
transgenes was identified by Southern blot analysis of SacI-
digested genomic DNA using 59 and 39 probes located outside the
homology regions used for gene recombination [27]. Mouse
chimeras were generated by C57BL/6 host blastocyst injection of
mutant embryonic stem cell clones, and the chimeras obtained
were bred with C57BL/6 mice to generate heterozygous Cthrc1
mice. Heterozygous mutants were then backcrossed eight times
with C57BL/6 mice to generate mutant mice with a C57BL/6
genetic background. We then performed RT-PCR to determine
the presence of Cthrc1 transcripts. We used the following primers of
Cthrc1 for RT-PCR, based on exon3 and exon4: 59-CTGCG-
AGTTCTGTTCAGTGG-39 and 59-GGGACTGAAATCGTC-
AGAGG-39. Cthrc1 transgenic mice were generated using an
osteoblast-specific 2.3-kb Col1a1 promoter, the 1.25-kb 36HA-
tagged full-length mouse Cthrc1 cDNA, and the 240-bp SV40
polyadenylation signal [28]. DNAs were injected into pronuclei of
fertilized C57BL/66DBA/2 hybrid eggs, and the injected eggs
were then transferred into CD1 foster mothers. Hemizygous
mutants were backcrossed eight times with C57BL/6 mice to
generate transgenic mice with a C57BL/6 genetic background.
The tissue specificity of transgene expression was examined in
immunohistochemistry studies. Routine mouse genotyping was
performed by PCR. The following primer pairs were used: 59-
CATCAAGATGGTATAAAAGG-39 and 59-GCAGCAGCAG-
CACAAGGAAG-39. The experimental protocols were approved
by the Animal Care and Use Committee of Kyoto University.
Histological analyses
Whole mount X-gal staining of embryos was performed as
previously described [29]. For the histological analyses, we fixed
embryos with 4% paraformaldehyde, embedded them in paraffin,
and sectioned them into 7-mm-thick slices. Immunohistochemical
staining was performed using peroxidase chromogens (Zymed)/
TrueBlue substrate (KPL) with rabbit polyclonal anti-HA antibody
(1:500, Covance). For in vivo BrdU labeling, 1-week-old mice were
injected intraperitoneally with 100 mg/kg BrdU (Amersham) and
sacrificed 3 hr later. Sections were stained with anti-BrdU
antibody (Amersham) and were counterstained with hematoxylin
according to the manufacturer’s instruction.
Micro-CT Analyses
High-resolution micro-CT scanning (SMX-100CT; Shimazu)
was performed to measure morphological indices of metaphyseal
regions of tibia as previously described [30]. Metaphyseal regions
were scanned 100 times with a slice increment of 8 mm. The most
proximal slice was defined as the plane where the growth plate had
just disappeared. Material properties were calculated using a
commercial software package (VG Studio Max1.2: Visual Science)
[30].
Bone Histomorphometry
The mice were injected subcutaneously with calcein (20 mg/kg
body weight; Sigma) 10 and 3 days before sacrifice. Fifth lumber
vertebrae were fixed with 4% paraformaldehyde for 18 hr at 4uC.
Undecalcified bones were embedded in methylmethacrylate, and
4-mm-thick sections were prepared for bone histomorphometric
analyses of adult mice as previously described [31]. Sections were
stained with 1% toluidine blue. Static and dynamic histomorpho-
metric analyses were performed according to standard protocols
using Histometry RT (SYSTEM-SUPPLY) [32,33].
Osteoblast Isolation and Culture
Primary osteoblasts were harvested from calvaria of newborn
mice by sequential collagenase digestion (Roche) and were
maintained in a-MEM containing 10% FBS. BrdU incorporation
was measured using the cell proliferation ELISA Biotrack kit
(Amersham).
Real-Time PCR
Primary osteoblasts were cultured in a-MEM containing 10%
FBS, 50 mg/ml ascorbic acid, and 10 nM b-glycerophosphate for
10 days, and total RNA was isolated from the cultured cells by
RNeasy Mini Kit (Qiagen) according to the manufacturer’s
instruction. Two mg of total RNA was reverse transcribed to
cDNA with the use of Transcriptor First Strand cDNA Synthesis
Kit (Roche). Real-time PCR was performed using the LightCycler
system with the FastStart DNA Master SYBR Green (Roche). The
following primers were used: G3pdh,5 9-TGTCCGTCGTGGAT-
CTGAC-39 and 59-CCTGCTTCACCACCTTCTTG-39; ALP,
59-ACTCAGGGCAATGAGGTCAC-39 and 59-CACCCGAGT-
GGTAGTCACAA -39; Col1a1,5 9-CTCCTGGCAAGAATGGA-
GAT-39 and 59-AATCCACGAGCACCCTGA-39; Osteocalcin,5 9-
AGACTCCGGCGCTACCTT-39 and 59-CTCGTCACAAG-
CAGGGTTAAG-39.
Measurement of CFU-ALP and CFU-O
Bone marrow cells were isolated as previously described [26].
Bone marrow cells from 5-week-old mice were plated into 12-well
plates at 2.5610
6 cells per well for CFU-ALP assays and at
5610
6 cells per well for CFU-O assays, and were cultured in a-
MEM containing 10% FBS, 50 mg/ml ascorbic acid, and 10 nM
b-glycerophosphate. For CFU-ALP assays, cultures were stained
at day 10 with Sigma alkaline phosphatase kit (Sigma), and
colonies with .20 cells were counted. Cultures were stained with
1% alizarin red S (Wako) at day 20 for the CFU-O assay of Cthrc1-
null mice, and at day 16 for that of Cthrc1 transgenic mice,
respectively. The stained area was calculated using the freeware
Image-J (NIH).
Ovariectomy
Mice were ovariectomized or sham-operated at 2 months of
age, and all of the mice were killed 4 weeks later and the tibiae and
vertebrae were removed for analyses.
Statistical analyses
Statistical analysis was performed by Student’s t test to
determine the significance between groups. Wild-type and
transgenic OVX and sham-operated mice were analyzed by
ANOVA followed by Fisher’s protected least significant difference.
Values were considered statistically significant at p,0.05.
More methods were shown in Supporting Information Text S1.
Supporting Information
Figure S1 Analyses of Cthrc1 expression in vitro and in vivo by
northern blot and in situ hybridization. (A) Effect of BMP2 (1 mg/
ml) on Cthrc1 expression in ATDC5 cells. Cthrc1 expression is
upregulated by BMP2. (B) Expression of Cthrc1 in various cell
lines. (C) Expression of Cthrc1 in adult mouse tissues. (D) In situ
hybridization analysis of Cthrc1 expression in limb buds of E13.5
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embryogenesis.
Found at: doi:10.1371/journal.pone.0003174.s001 (8.89 MB TIF)
Figure S2 Skeletal preparation of Cthrc1-null and Cthrc1
transgenic mice. (A) Whole-mount X-gal staining of heterozygous
Cthrc1 embryos during embryogenesis. (B and C) Skeletons of
newborn Cthrc1-null mice (B) and Cthrc1 transgenic mice (C)
stained by alcian blue followed by alizarin red. WT: wild-type
mice; KO: Cthrc1-null mice; Tg: Cthrc1 transgenic mice.
Found at: doi:10.1371/journal.pone.0003174.s002 (5.91 MB TIF)
Figure S3 In situ hybridization analyses of osteoblast and
chondrocyte marker genes in Cthrc1-null and Cthrc1 transgenic
mouse embryos. Runx2, Col1a1, Col2a1 and Col10a1 expression
in humeri of E16.5 embryos. (A) Cthrc1-null mouse embryos. (B)
Cthrc1 transgenic mouse embryos. WT: wild-type mice; KO:
Cthrc1-null mice; Tg: Cthrc1 transgenic mice.
Found at: doi:10.1371/journal.pone.0003174.s003 (10.15 MB
TIF)
Figure S4 Effect of Cthrc1 on osteoclastogenesis. (A) TRAP
staining of vertebrae of 2-month-old Cthrc1-null and wild-type
mice. TRAP-positive osteoclast number/bone surface (Oc.N/BS)
and osteoclast surface/bone surface (Oc.S/BS) are shown (n=6).
(B) Expression of RANKL in primary osteoblasts harvested from
Cthrc1-null mice, assessed by real-time PCR. (C) TRAP staining
of vertebrae of 2-month-old Cthrc1 transgenic and wild-type mice.
TRAP-positive osteoclast number/bone surface (Oc.N/BS) and
osteoclast surface/bone surface (Oc.S/BS) are shown (n=6). (D)
Expression of RANKL in primary osteoblasts harvested from
Cthrc1 transgenic mice, assessed by real-time PCR. WT: wild-type
mice; KO: Cthrc1-null mice; Tg: Cthrc1 transgenic mice. Data
are shown as the mean6SEM (*p,0.05).
Found at: doi:10.1371/journal.pone.0003174.s004 (9.83 MB TIF)
Text S1 Supplementary Methods.
Found at: doi:10.1371/journal.pone.0003174.s005 (0.05 MB
DOC)
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